|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA ´Ù¼ö ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.04 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Clinical Project Leader
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
09.02 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)CRA ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
07.24 |
|
|
ÀÌ¿ÀÇ÷οì ÁÖ½Äȸ»ç |
[ÀÌ¿ÀÇ÷οì] CRA ä¿ë(°ú/Â÷Àå)
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.04 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)CRA ´Ù¼ö ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
05.21 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA 0¸í ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
½Ã¹ÍÄÚ¸®¾Æ |
½Ã¹ÍÄÚ¸®¾Æ CRA II / Senior CRA °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
02.07 |
|
|
ÆĹ̼¿(ÁÖ) |
ÆĹ̼¿(ÁÖ) ÀÓ»óÆÀ °æ·ÂÁ÷ ä¿ë°ø°í
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
01.19 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Contract Represent
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
11.14 |
|
|
PRA Health Sciences |
[PRA Health Sciences] CRA I, II, III, Drug Safety Associ
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.28 |
|
|
PRA Health Sciences |
CRA, Sr. CRA
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
04.18 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ Á¤±ÔÁ÷ CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
12.08 |
|
|
(ÁÖ)º§¸óÆ®¸®½áÄ¡ |
(ÁÖ)º§¸óÆ®¸®½áÄ¡ ½ÅÀÔ / °æ·Â CRA ¸ðÁý
¼¿ï ¼ºµ¿±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.24 |
|
|
(ÁÖ)Áö¿¡½º½ºÅÄ´Ùµå |
CRA, PMä¿ë
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
02.12 |
|
|
¾ËÇÇ¿¡½º¸®¼Ä¡ |
¹Ì±¹°è Global CRO Company ÀÇ CRA ä¿ë (for Global Projec
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
»ó½Ãä¿ë |
09.03 |
|